U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07704385) titled 'Enhancing Rehabilitation in Aging Study (ERAS)' on July 10.
Brief Summary: Acute Intermittent Hypoxia (AIH) is a rehab approach attributed to serotonin. AIH signaling also occurs via adenosine, and the pathways inhibit each other. Increased neural adenosine in aging may stymie AIH plasticity. The hypothesis is pre-treatment with adenosine 2A receptor inhibition (A2AI) enhances AIH effects on motor plasticity in unaffected adults. AIH exposures will be paired with A2AI or placebo, with a 4-week washout. Primary outcome measures include inspiratory and grip strength.
Study Start Date: Oct. 01, 2026
Study Type: INTERVENTIONAL
Condit...